Sign In
Buy DERM
$6.43
+0.210 (+3.38%)
At Close: Jun 22, 2026
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
04:45pm, Tuesday, 19'th May 2026
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical comp
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
07:30pm, Wednesday, 13'th May 2026
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates
06:15pm, Wednesday, 13'th May 2026
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.18 per share a year ago.
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
04:01pm, Wednesday, 13'th May 2026
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position i
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
10:00am, Thursday, 07'th May 2026
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM). Such investors are advise
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
04:01pm, Wednesday, 06'th May 2026
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c
Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know
11:01am, Wednesday, 06'th May 2026
Journey Medical (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
10:40pm, Thursday, 30'th Apr 2026
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM). Such investors are a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
04:57pm, Tuesday, 28'th Apr 2026
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation (“Journey” or the “Company”) (NASDAQ: DERM). Such inv
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
08:30am, Tuesday, 21'st Apr 2026
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
10:00am, Thursday, 16'th Apr 2026
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM). Such investors are a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
04:49pm, Tuesday, 14'th Apr 2026
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation (“Journey” or the “Company”) (NASDAQ: DERM). Such inv
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
10:00am, Thursday, 09'th Apr 2026
NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM). Such investors are a
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Journey Medical Corporation (NASDAQ: DERM). The investigation focuses on
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts
04:42am, Wednesday, 01'st Apr 2026
Journey Medical Corporation (NASDAQ: DERM - Get Free Report) has been assigned an average recommendation of "Hold" from the five research firms that are presently covering the company, Marketbeat repo
